David Arkowitz

Insider Reports History

Identity 1 identity field
Location
Burlington, MA
SEC source record 1 source field
Owner filing signature
/s/ Marc Banjak, Attorney-in-fact
Source evidence 1 source field
Transaction evidence
Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for David Arkowitz

Form 4 holding Chief Financial Officer

Flexion Therapeutics Inc

Security class
Common Stock
Shares / value
220,719
Estimated value
$1,876,112
Report date
10 May 2021
Price
$8.50
Ownership
Direct
Form 4 holding Chief Financial Officer

Seres Therapeutics, Inc.

Security class
Common Stock
Shares / value
182,442
Estimated value
$197,037
Report date
16 Feb 2024
Price
$1.08
Ownership
Direct
Form 4 holding Director

iBio, Inc.

Security class
Common Stock
Shares / value
18,382
Estimated value
$49,999
Report date
10 Jan 2025
Price
$2.72
Ownership
Direct
Form 4 holding Chief Financial Officer

Seres Therapeutics, Inc.

Security class
Restricted Stock Units
Shares / value
31,875
Estimated value
$43,031
Report date
15 Feb 2024
Price
$1.35
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Chief Financial Officer

Seres Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
287,905
Estimated value
Report date
14 Feb 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

iBio, Inc.

Security class
Stock Option (right to buy)
Shares / value
13,500
Estimated value
Report date
20 Nov 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

F-star Therapeutics, Inc.

Security class
Warrant (right to buy)
Shares / value
0
Estimated value
Report date
20 Nov 2020
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

KINETA, INC./DE

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
30 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by David Arkowitz

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .